The Association of the British Pharmaceutical Industry
Medicines are transforming our lives like never before.
We want the UK to be the best place in the world to research, develop and use the medicines and vaccines of the future.
Latest news and blogs
News |
ABPI launches manifesto to make Scotland a leader in R&D and cutting-edge medicines
News |
UK tumbles down global rankings for pharma investment and research
News |
The UK risks undervaluing life sciences manufacturing investment
Blog |
UK medicines investment: the case for improving the UK commercial environment
Best practice guidance: Supporting patient organisations to report industry funding
Transparency is essential when pharmaceutical companies work with patient organisations. This updated guidance is aimed at supporting that transparency.
Guidance for conferences and events in the UK: ABPI Code of Practice requirements
This clarifies the ABPI Code requirements for conferences and events, helps all relevant stakeholders operate in a Code-compliant, professional and ethical manner.
2024 ABPI Code of Practice – new resources
The PMCPA has published new webinars and e-learning to aid understanding of the 2024 ABPI Code of Practice.
Lives Lived Well
From patients and their loved ones to those working within the pharmaceutical industry in the UK, we share a common goal: Lives Lived Well.
Events
NICE/DSU/ABPI masterclass – Methods for the analysis of non-randomised, patient level data for the estimation of treatment effects
Save the date - ABPI Industry Summit 2025
ABPI Annual Conference 2026
ABPI’s flagship annual conference will be taking place in Central London on 23 April 2026.
Companies granted extension to VPAG 2026 decision deadline
The ABPI and the government have agreed to a four-week extension to the deadline by which companies must give notice if they intend to leave the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG). The revised deadline for submitting notice to leave the VPAG scheme is 31 October 2025.
Key facts and figures for the pharmaceutical industry in the UK
£46.7bn
Turnover [6]
£9bn
investment in UK R&D (more than UKRI’s entire annual budget) [3]
£17.6bn
direct Gross Value Added (GVA) [1]